Dechra Pharmaceuticals Aktie
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 753 | 1 889 | 1 975 | 2 163 | 2 457 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,27 | 0,27 | 0,31 | 0,32 | 0,31 |
Bilanz (in Mio. GBP) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 292 | 449 | 392 | 444 | 468 |
| Summe Anlagevermögen | 756 | 789 | 822 | 849 | 1 102 |
| Summe Aktiva | 1 049 | 1 238 | 1 214 | 1 293 | 1 569 |
Bilanz (in Mio. GBP) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 539 | 600 | 581 | 627 | 814 |
| Summe Eigenkapital | 509 | 638 | 633 | 667 | 755 |
| Summe Passiva | 1 049 | 1 238 | 1 214 | 1 293 | 1 569 |
Adresse
| Cheshire Business Park, CW9 7UA Northwich | |
| Telefon | +44 (16) 0681-4730 |
| Fax | +44 (16) 0681-4731 |
| Internet | http://www.dechra.com |
Management
|
Anthony Lucas
Group Director-Product Development |
|
Jamie Adams
Chief Information Officer |
|
Jesper Nordengaard
Chief Executive Officer |
|
John Francis Shipsey
Non-Executive Director |
|
Katy Clough
Chief People Officer |
|
Lawson Macartney
Senior Independent Non-Executive Director |
|
Lisa Jane Bright
Non-Executive Director |
|
Michael Bauer
Director |
|
Patrick Meeus
Group Scientific Officer |
|
Paul Sandland
Chief Financial Officer & Executive Director |
|
Sherilyn D. McCoy
Chairman |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.